Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:IPA NASDAQ:IVVD NASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$5.86+3.2%$6.20$4.34▼$11.35$352.84M0.45292,754 shs339,934 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.27▼$3.25$96.68M0.531.83 million shs1.97 million shsIVVDInvivyd$2.23+14.9%$1.27$0.35▼$2.74$415.95M0.576.66 million shs6.79 million shsREPLReplimune Group$8.80+4.5%$5.36$2.68▼$17.00$657.23M0.428.59 million shs2.19 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+3.17%+3.35%-5.02%-18.95%-48.60%IPAImmunoPrecise Antibodies0.00%0.00%0.00%-3.01%+289.69%IVVDInvivyd+14.95%+28.16%+82.79%+184.08%+125.66%REPLReplimune Group+4.51%+95.56%+111.54%+179.37%-26.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$5.86+3.2%$6.20$4.34▼$11.35$352.84M0.45292,754 shs339,934 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.19$0.27▼$3.25$96.68M0.531.83 million shs1.97 million shsIVVDInvivyd$2.23+14.9%$1.27$0.35▼$2.74$415.95M0.576.66 million shs6.79 million shsREPLReplimune Group$8.80+4.5%$5.36$2.68▼$17.00$657.23M0.428.59 million shs2.19 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+3.17%+3.35%-5.02%-18.95%-48.60%IPAImmunoPrecise Antibodies0.00%0.00%0.00%-3.01%+289.69%IVVDInvivyd+14.95%+28.16%+82.79%+184.08%+125.66%REPLReplimune Group+4.51%+95.56%+111.54%+179.37%-26.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.67Moderate Buy$20.50249.83% UpsideIPAImmunoPrecise Antibodies 3.00Buy$4.0090.93% UpsideIVVDInvivyd 2.57Moderate Buy$5.14130.38% UpsideREPLReplimune Group 2.45Hold$11.0025.00% UpsideCurrent Analyst Ratings BreakdownLatest IPA, IVVD, AURA, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025REPLReplimune GroupLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/20/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$13.0010/20/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$11.0010/20/2025REPLReplimune GroupLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$3.00 ➝ $13.0010/20/2025REPLReplimune GroupWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$4.00 ➝ $18.0010/15/2025IVVDInvivydZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/14/2025REPLReplimune GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AURAAura BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IVVDInvivydWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.00 ➝ $2.0010/6/2025IVVDInvivydCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$10.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/AIPAImmunoPrecise Antibodies$17.59M5.50N/AN/A$0.37 per share5.66IVVDInvivyd$25.38M18.84N/AN/A$0.56 per share3.98REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$86.92M-$1.96N/AN/AN/AN/A-64.44%-54.24%11/11/2025 (Estimated)IPAImmunoPrecise Antibodies-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%12/10/2025 (Estimated)IVVDInvivyd-$169.93M-$0.92N/A20.27N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)REPLReplimune Group-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)Latest IPA, IVVD, AURA, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025IVVDInvivyd-$0.01N/AN/AN/A$12.00 millionN/A11/11/2025Q3 2025AURAAura Biosciences-$0.46N/AN/AN/AN/AN/A11/11/2025Q2 2026REPLReplimune Group-$0.86N/AN/AN/A$0.50 millionN/A8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/13/2025Q2 2025AURAAura Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A8/7/2025Q1 2026REPLReplimune Group-$0.83-$0.95-$0.12-$0.95$0.50 millionN/A7/29/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.3912.39IPAImmunoPrecise Antibodies0.492.081.85IVVDInvivydN/A1.331.33REPLReplimune Group0.216.946.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%IPAImmunoPrecise Antibodies6.70%IVVDInvivyd70.36%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences6.30%IPAImmunoPrecise Antibodies6.83%IVVDInvivyd25.40%REPLReplimune Group5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5062.12 million58.21 millionNot OptionableIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableIVVDInvivyd100214.41 million159.95 millionOptionableREPLReplimune Group21078.06 million74.00 millionOptionableIPA, IVVD, AURA, and REPL HeadlinesRecent News About These CompaniesThe Best AI for Picking Stocks, Ranked by Performance (REPL)...October 23 at 2:38 PM | marketbeat.comReplimune Group FY2027 EPS Decreased by Leerink PartnrsOctober 23 at 8:02 AM | marketbeat.comReplimune Group (REPL) Is Up 86.2% After FDA Accepts Resubmitted RP1 Application for Advanced Melanoma—Has The Bull Case Changed?October 22 at 3:54 PM | finance.yahoo.comWedbush Issues Positive Outlook for Replimune Group EarningsOctober 22 at 8:20 AM | marketbeat.comBarclays Keeps Their Hold Rating on Replimune Group (REPL)October 22 at 7:42 AM | theglobeandmail.comKLP Kapitalforvaltning AS Has $70,000 Stock Holdings in Replimune Group, Inc. $REPLOctober 22 at 5:01 AM | defenseworld.netDJP Morgan Upgrades Replimune Group (REPL)October 21, 2025 | msn.comWedbush Upgrades Replimune Group (REPL)October 21, 2025 | msn.comReplimune (REPL) Stock: Biotech Shares Surge 100% on Regulatory BreakthroughOctober 21, 2025 | blockonomi.comReplimune bounces back on FDA acceptance of BLAOctober 21, 2025 | thepharmaletter.comTA Look at Replimune Group’s (REPL) Valuation Following Promising IGNYTE Phase 2 Melanoma Trial ResultsOctober 21, 2025 | finance.yahoo.comLeerink Partnrs Upgrades Replimune Group (NASDAQ:REPL) to "Strong-Buy"October 21, 2025 | marketbeat.comReplimune: Acceptance Confirms Completeness, Not Approval (Rating Upgrade)October 21, 2025 | seekingalpha.comReplimune Group, Inc. $REPL Shares Bought by TD Asset Management IncOctober 21, 2025 | marketbeat.comWhy Replimune Stock Was Soaring TodayOctober 20, 2025 | fool.comReplimune Group (NASDAQ:REPL) Upgraded by Piper Sandler to "Overweight" RatingOctober 20, 2025 | marketbeat.comPromising Biotech Stocks To Follow Now - October 20thOctober 20, 2025 | marketbeat.comJPMorgan Chase & Co. Upgrades Replimune Group (NASDAQ:REPL) to "Neutral"October 20, 2025 | marketbeat.comReplimune's FDA BLA Resubmission for RP1: A New Hope for Advanced Melanoma TreatmentOctober 20, 2025 | sohu.comSWhat Is Driving Replimune Stock’s 98% Surge Today?October 20, 2025 | msn.comReplimune Group (NASDAQ:REPL) Shares Gap Up Following Analyst UpgradeOctober 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Sprouts, Darden Offer High-Upside Setups for Risk-TakersBy Sam Quirke | September 26, 2025Café Culture Revival? 3 Stocks to Watch After Chick-fil-A’s MoveBy Chris Markoch | October 9, 2025The New Brain of Business: UiPath Is Creating an AI RevolutionBy Jeffrey Neal Johnson | October 2, 2025Silver Also Glitters: 3 ETFs to Ride The Precious Metals SurgeBy Dan Schmidt | October 20, 2025IPA, IVVD, AURA, and REPL Company DescriptionsAura Biosciences NASDAQ:AURA$5.86 +0.18 (+3.17%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.95 +0.09 (+1.54%) As of 10/24/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.ImmunoPrecise Antibodies NASDAQ:IPAImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Invivyd NASDAQ:IVVD$2.23 +0.29 (+14.95%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.23 0.00 (0.00%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Replimune Group NASDAQ:REPL$8.80 +0.38 (+4.51%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$8.66 -0.14 (-1.53%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
